Growth in the Blood Systems business centered on apheresis, cell processing and emerging markets

「テルモが米 CSLベーリング子会社向け血漿採取装置の供給契約を解除したと発表した。」

「Overseas, Global Blood Solutions remained strong as the plasma innovation business expanded more rapidly in North America, resulting in a 15.5% increase in revenue from the previous fiscal year. In Japan, revenue from blood-collection-related products increased, rising 13.2% from the previous fiscal year.」

「Global Blood Solutions remained strong as the plasma innovation business expanded more rapidly in North America, resulting in global revenue increasing 9.2% year on year to ¥107.1 billion.」

「Overseas, Global Blood Solutions, formerly the business serving blood centers, remained strong, driven by the accelerated expansion of the plasma innovation business in North America and increased revenue from blood-collection-related businesses in Europe and the United States, resulting in a 20.3% increase in revenue from the previous fiscal year.」

「Overseas, business with blood centers remained strong, particularly in the Americas, resulting in a 17.1% year-on-year increase in revenue. In Japan, revenue from products for blood centers also increased, rising 8.7% year on year. As a result, global revenue increased 16.5% year on year to ¥98.0 billion.」

「The Reveos automated blood component processing system obtained certification from the US Food and Drug Administration (FDA). Reveos is a system for producing blood products, including platelet products, from whole blood collected from donors through whole-blood collection, and is used in 52 countries worldwide. Following this FDA certification, Terumo plans to expand sales of Reveos to blood centers across the US as the first automated whole-blood processing system in the country.」

「Overseas, business with blood centers in the Americas, Asia and other regions remained strong, resulting in a 13.1% year-on-year increase in revenue. In Japan, revenue from products related to component collection increased, resulting in a 7.3% year-on-year increase. As a result, global revenue increased 12.7% year on year to ¥127.8 billion.」

「Overseas, the blood-center business performed strongly in Asia and other regions, Europe and the US, resulting in a 14.5% year-on-year increase in revenue. In Japan, sales of apheresis-related products increased, resulting in 3.8% year-on-year revenue growth. As a result, global revenue increased 13.7% year on year to ¥84.1 billion.」

「Overseas, the blood-center business performed strongly due to demand for apheresis machines in North America and expanding transfusion demand in Asia and other regions, resulting in a 20.2% year-on-year increase in revenue. As a result, global revenue increased 18.8% year on year to ¥40.9 billion.」

「At a CSL Plasma plasma collection center in Aurora, Colorado, US, the first plasma collection from a donor using the Rika source plasma collection system was completed.」

「In Japan, revenue declined due to the delayed recovery in medical demand. Overseas revenue increased sharply by 29.0% year on year, driven by the recovery in transfusion demand in Asia and other regions and strong demand for apheresis machines in North America. As a result, global revenue increased 25.8% year on year to ¥113.4 billion.」

「In Japan, revenue declined slightly, mainly from products for blood centers. Overseas, demand for whole-blood collection, apheresis therapy and cell processing products recovered, resulting in a 12.0% year-on-year increase in global revenue to ¥58.2 billion. During the cumulative second-quarter period, the company began selling its source plasma collection system in the US.」

「Overseas, recovering demand for products for blood centers, mainly in Asia and North America, resulted in a 21.8% year-on-year increase in global revenue to ¥34.5 billion.」

「Rika, a source plasma collection system developed by Terumo, obtained 510(k) clearance from the US Food and Drug Administration (FDA). Rika is designed to keep collection time to an average of 35 minutes or less and the volume of blood circulating outside the body to 200 mL or less.」

「In Japan, revenue declined slightly, mainly from products for blood centers. Overseas, demand for whole-blood collection, apheresis therapy and cell processing products recovered, resulting in an 11.3% year-on-year increase in global revenue to ¥90.2 billion.」

「In Japan, revenue declined slightly, mainly from products for blood centers. Overseas, demand for whole-blood collection, apheresis therapy and cell processing products recovered, resulting in a 12.0% year-on-year increase in global revenue to ¥58.2 billion.」

「In Japan, revenue from products for blood centers declined slightly. Overseas, demand for whole-blood collection, apheresis therapy products and cell processing products recovered, resulting in a 14.4% year-on-year increase in global revenue to ¥28.3 billion.」

「Overseas, demand for apheresis therapy products and cell processing products declined due to the same impact, but demand for COVID-19 convalescent plasma increased and new software for apheresis machines drove sales. As a result, revenue for the Blood and Cell Technologies Company increased 2.2% from the previous fiscal year to ¥109.5 billion.」

「In Japan, revenue declined slightly as demand for blood fell due to the spread of COVID-19. Overseas, demand for apheresis therapy products and cell processing products declined due to the same impact, but demand for COVID-19 convalescent plasma increased and new software for apheresis machines drove sales. As a result, revenue for the Blood and Cell Technologies Company increased 2.9% year on year to ¥81.0 billion.」

「In Japan, revenue from products for blood centers declined in response to lower demand for blood resulting from the spread of COVID-19. Overseas, demand for apheresis therapy products and cell processing products declined due to the same impact, but new software for apheresis machines drove sales and demand for COVID-19 convalescent plasma increased. As a result, revenue for the Blood and Cell Technologies Company increased 0.4% year on year to ¥52.0 billion.」

「Overseas, demand for apheresis therapy products declined due to this impact, but new software for apheresis machines drove sales, and demand for convalescent plasma for COVID-19 increased. As a result, revenue for the Blood and Cell Technologies Company increased 2.2% year on year to ¥24.7 billion.」

「The Blood and Cell Technologies Company will pursue expansion into new therapeutic areas, generate innovation and promote diversification.」

「In Japan, sales of products for blood centers remained steady, resulting in higher revenue. Overseas performance was also strong, driven by the introduction of new software for apheresis machines, but the negative impact of foreign exchange in Europe and emerging markets limited growth. As a result, revenue for the Blood Systems Company increased 2.8% year on year to ¥78.7 billion.」

「In Japan, sales of products for blood centers remained steady, resulting in higher revenue. Overseas, products for blood centers performed steadily in the US and strongly in emerging markets, including through the acquisition of tenders. As a result, revenue for the Blood Systems Company increased 3.2% year on year to ¥51.8 billion.」

「In Japan, sales of products for blood centers remained steady, resulting in higher revenue. Overseas, cell processing products performed well, but sales of products for blood centers were affected by the reversal of strong performance at the end of the previous fiscal year and negative foreign exchange effects in Europe and emerging markets. As a result, revenue for the Blood Systems Company decreased 1.6% year on year to ¥24.2 billion.」

「The Quantum cell expansion system was introduced by China-based Unicar Therapy Biomedicine Technology Co., Ltd. to automate the manufacturing (culturing) process for chimeric antigen receptor T-cell (CAR-T) products. In June 2018, the company also obtained US Food and Drug Administration (FDA) approval for 4% (w/v) sodium citrate dihydrate anticoagulant manufactured at Terumo BCT's Larn, UK plant.」

「Apheresis therapy products posted lower revenue due to special demand in the US in the same period of the previous year. However, supported by steady sales of products for blood centers in Japan and Central and South America, revenue for the Blood Systems Company increased 0.1% year on year to ¥76.6 billion.」

「Sales to blood centers remained strong, mainly in the Americas and Japan. Sales revenue in the apheresis treatment field also grew in Europe. As a result, sales revenue at the Blood Systems Company increased 1.9% year on year to ¥50.2 billion.」

「Sales to blood centers remained strong, mainly in North America and emerging markets. Sales revenue in the apheresis treatment field also grew in Europe. As a result, sales revenue at the Blood Systems Company increased 5.4% year on year to ¥24.6 billion.」

「Japan’s first formal adoption of the TACSI automated blood component processing system for blood centers was decided. The system enables efficient, consistent and high-quality centrifugation of whole blood, and is scheduled for phased introduction at blood centers nationwide from fiscal 2018. In the United States, clinical trials of Mirasol, a pathogen-reduction system, began.」

「Sales of products for blood centers remained strong in Latin America and Asia. Sales of products in the apheresis treatment field also grew, driven mainly by replacement demand in North America. As a result, sales at the Blood Systems Company increased 11.4% year on year to ¥76.5 billion.」

「Sales of products for blood centers remained strong in Latin America and Asia. Sales in the apheresis treatment field also grew, led by North America. As a result, sales at the Blood Systems Company increased 8.8% year on year to ¥49.2 billion.」

「Sales to blood centers remained strong in Latin America and Asia. Sales in the apheresis treatment field also grew, led by the Americas.」

「In the blood center field, the company will focus on expanding sales of its next-generation platform for its component blood collection system, which has a global share of more than 50%, to further strengthen its current position. It will also promote global adoption of pathogen-reduction systems that improve transfusion safety through clinical trials and other initiatives in the United States. In the blood treatment systems field, the company will focus on expanding the applications of apheresis treatment, mainly for autoimmune diseases, to further strengthen its No. 1 global position.」

「In the blood field, in addition to rising demand for apheresis treatment for conditions such as immune diseases, expectations are also growing for cell processing as cell therapy expands.」

「In the blood field, demand is increasing not only for transfusion therapy but also for apheresis treatment for conditions such as immune diseases.」

「In the blood field, demand is increasing not only for transfusion therapy but also for apheresis treatment for conditions such as immune diseases.」

「The Blood Systems Company aims for sustainable growth by steadily capturing rising healthcare demand in emerging markets and increasing sales in the apheresis treatment and cell processing fields.」